These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27333031)

  • 21. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
    Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
    Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
    Min JW; Lee H; Choi BS; Park CW; Yang CW; Kim YS; Choi YJ; Oh EJ; Chung BH
    Ann Lab Med; 2018 Sep; 38(5):450-457. PubMed ID: 29797816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection.
    Slavcev A; Lácha J; Honsová E; Sajdlová H; Lodererová A; Vitko S; Skibová J; Striz I
    Transpl Immunol; 2005 Jun; 14(2):117-21. PubMed ID: 15935302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation.
    Hamer R; Roche L; Smillie D; Harmer A; Mitchell D; Molostvov G; Lam FT; Kashi H; Tan LC; Imray C; Fletcher S; Briggs D; Lowe D; Zehnder D; Higgins R
    Transpl Immunol; 2010 Aug; 23(4):161-5. PubMed ID: 20600903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation.
    Kim MS; Kim HJ; Kim SI; Ahn HJ; Ju MK; Kim HJ; Jeon KO; Kim YS
    Transplantation; 2006 Dec; 82(12):1602-5. PubMed ID: 17198243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting renal graft failure by sCD30 levels and de novo HLA antibodies at 1year post-transplantation.
    Wang D; Wu G; Chen J; Yu Z; Wu W; Yang S; Tan J
    Transpl Immunol; 2012 Jun; 26(4):235-9. PubMed ID: 22446727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant.
    Domingues EM; Matuck T; Graciano ML; Souza E; Rioja S; Falci MC; Monteiro de Carvalho DB; Porto LC
    Clin Transplant; 2010; 24(6):821-9. PubMed ID: 20047612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients.
    Billing H; Sander A; Süsal C; Ovens J; Feneberg R; Höcker B; Vondrak K; Grenda R; Friman S; Milford DV; Lucan M; Opelz G; Tönshoff B
    Transpl Int; 2013 Mar; 26(3):331-8. PubMed ID: 23279372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-transplant low level HLA antibody shows a composite poor outcome in long-term outcome of renal transplant recipients.
    Tian J; Li D; Alberghini TV; Rewinski M; Guo N; Bow LM
    Ren Fail; 2015 Mar; 37(2):198-202. PubMed ID: 25565259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation.
    Caillard S; Becmeur C; Gautier-Vargas G; Olagne J; Muller C; Cognard N; Perrin P; Braun L; Heibel F; Lefebre F; Renner V; Gachet C; Moulin B; Parissiadis A
    Transpl Int; 2017 Jan; 30(1):29-40. PubMed ID: 27678382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.
    Guidicelli G; Guerville F; Lepreux S; Wiebe C; Thaunat O; Dubois V; Visentin J; Bachelet T; Morelon E; Nickerson P; Merville P; Taupin JL; Couzi L
    J Am Soc Nephrol; 2016 Feb; 27(2):615-25. PubMed ID: 26047793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
    Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
    Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.
    Smith JD; Ibrahim MW; Newell H; Danskine AJ; Soresi S; Burke MM; Rose ML; Carby M
    J Heart Lung Transplant; 2014 Oct; 33(10):1074-82. PubMed ID: 24954882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
    Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
    Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations.
    Cinti P; Pretagostini R; Arpino A; Tamburro ML; Mengasini S; Lattanzi R; De Simone P; Berloco P; Molajoni ER
    Transplantation; 2005 May; 79(9):1154-6. PubMed ID: 15880060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of pre- and post-transplant HLA antibodies, donor-specific, and nondonor-specific HLA antibodies detected by ELISA in renal transplantation.
    Lee PC; Chen YL; Wang WM; Tu WC; Chen HY
    Clin Transpl; 2013; ():385-91. PubMed ID: 25095533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.